Preconditioning of human mesenchymal stem cells to enhance their regulation of the immune response

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Saparov, Arman ^a   Ogay, Vyacheslav ^b   Nurgozhin, Talgat ^c   Jumabay, Medet ^d   Chen, William C W ^e  

^a NAZARBAYEV UNIVERSITY   (Kazakhstan)

^b NATIONAL CENTER FOR BIOTECHNOLOGY   (Kazakhstan)

^c NAZARBAYEV UNIVERSITY   (Kazakhstan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Massachusetts Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NATURAL KILLER CELL RECEPTOR NKG2A; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL HYPOXIA; CELL SURVIVAL; ENGRAFTMENT; EX VIVO STUDY; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL; OXYGEN SUPPLY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION;

EID: 84994796635     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/3924858     Document Type: Review

References (71)

1. A. I. CaplanandD.Correa, "TheMSC: aninjurydrugstore," Cell Stem Cell, vol. 9, no. 1, pp. 11-15, 2011.
2. A. Saparov, C.-W. Chen, S. A. Beckman, Y.Wang, and J. Huard, "The role of antioxidation and immunomodulation in postnatal multipotent stem cell-mediated cardiac repair," International Journal of Molecular Sciences, vol. 14, no. 8, pp. 16258-16279, 2013.
3. Y. Wang, X. Chen, W. Cao, and Y. Shi, "Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications,"Nature Immunology, vol. 15,no. 11,pp. 1009-1016, 2014.
4. Q.Chen, P. Shou,C. Zheng et al., "Fate decision ofmesenchymal stemcells: adipocytes or osteoblasts?" Cell Death & Differentiation, vol. 23, pp. 1128-1139, 2016.
5. S. Kokabu, J. W. Lowery, and E. Jimi, "Cell fate and differentiation of bone marrow mesenchymal stem cells," Stem Cells International, vol. 2016,Article ID 3753581, 7 pages, 2016.
6. H. Tao, Z. Han, Z. C. Han, and Z. Li, "Proangiogenic features of mesenchymal stem cells and their therapeutic applications," Stem Cells International, vol. 2016, Article ID 1314709, 11 pages, 2016.
7. W. Faiella and R. Atoui, "Immunotolerant properties of mesenchymal stem cells: updated review," Stem Cells International, vol. 2016, Article ID 1859567, 7 pages, 2016.
8. M. E. Bernardo and W. E. Fibbe, "Mesenchymal stromal cells: sensors and switchers of inflammation," Cell Stem Cell, vol. 13, no. 4, pp. 392-402, 2013.
9. M. Najar, G. Raicevic, H. Fayyad-Kazan et al., "Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells," Cytotherapy, vol. 18, no. 2, pp. 160-171, 2016.
10. A. Uccelli and N. K. Rosbo, "The immunomodulatory function of mesenchymal stem cells: mode of action and pathways," Annals of the New York Academy of Sciences, vol. 1351, no. 1, pp. 114-126, 2015.
11. A. Trounson and C. McDonald, "Stem cell therapies in clinical trials: progress and challenges," Cell Stem Cell, vol. 17, no. 1, pp. 11-22, 2015.
12. F. Gao, S. M. Chiu, D. A.Motan et al., "Mesenchymal stem cells and immunomodulation: current status and future prospects," Cell Death & Disease, vol. 7, no. 1, p. e2062, 2016.
13. A. M. Bader, K. Klose, K. Bieback et al., "Hypoxic preconditioning increases survival and pro-angiogenic capacity of human cord blood mesenchymal stromal cells in vitro," PLoS ONE, vol. 10, no. 9, Article ID e0138477, 2015.
14. S. T. Hsiao, R. J. Dilley, G. J. Dusting, and S. Y. Lim, "Ischemic preconditioning for cell-based therapy and tissue engineering," Pharmacology andTherapeutics, vol. 142, no. 2,pp. 141-153, 2014.
15. I. Rosova, M. Dao, B. Capoccia, D. Link, and J. A. Nolta, "Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells," STEM CELLS, vol. 26, no. 8, pp. 2173-2182, 2008.
16. J. Beegle, K. Lakatos, S. Kalomoiris et al., "Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo," STEM CELLS, vol. 33, no. 6, pp. 1818-1828, 2015.
17. Y. S. Kim, M. Y. Noh, K. A. Cho et al., "Hypoxia/reoxygenationpreconditioned human bone marrow-derived mesenchymal stromal cells rescue ischemic rat cortical neurons by enhancing trophic factor release,"MolecularNeurobiology, vol. 52,no. 1, pp. 792-803, 2015.
18. S. S. Ho, K. C. Murphy, B. Y. Binder, C. B. Vissers, and J. K. Leach, "Increased survival and function of mesenchymal stem cell spheroids entrapped in instructive alginate hydrogels," Stem Cells Translational Medicine, vol. 5, no. 6, pp. 773-781, 2016.
19. K.C.Murphy, S. Y. Fang, andJ. K. Leach, "Humanmesenchymal stem cell spheroids in fibrin hydrogels exhibit improved cell survival and potential for bone healing," Cell and Tissue Research, vol. 357, no. 1, pp. 91-99, 2014.
20. Y. Xu, T. Shi, A. Xu, and L. Zhang, "3D spheroid culture enhances survival and therapeutic capacities of MSCs injected into ischemic kidney," Journal of Cellular andMolecular Medicine, vol. 20, no. 7, pp. 1203-1213, 2016.
21. D. J. Prockop, "Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation," STEM CELLS, vol. 31, no. 10, pp. 2042-2046, 2013.
22. A. I. Caplan and J. M. Sorrell, "The MSC curtain that stops the immune system," Immunology Letters, vol. 168, no. 2, pp. 136-139, 2015.
23. K. Le Blanc and D. Mougiakakos, "Multipotent mesenchymal stromal cells and the innate immune system," Nature Reviews Immunology, vol. 12, no. 5, pp. 383-396, 2012.
24. M. Krampera, "Mesenchymal stromal cell licensing: a multistep process," Leukemia, vol. 25, no. 9, pp. 1408-1414, 2011.
25. L. Chen, Y. Xu, J. Zhao et al., "Conditioned medium from hypoxic bone marrow-derived mesenchymal stem cells enhances wound healing in mice," PLoS ONE, vol. 9, no. 4, Article ID e96161, 2014.
26. C. Noone, A. Kihm, K. English, S. ODea, and B. P. Mahon, "IFN-stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro," Stem Cells and Development, vol. 22, no. 22, pp. 3003-3014, 2013.
27. M. Francois, R. Romieu-Mourez, M. Li, and J. Galipeau, "Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystanderM2 macrophage differentiation," Molecular Therapy, vol. 20, no. 1, pp. 187-195, 2012.
28. H. Fan, G. Zhao, L. Liu et al., "Pre-treatment with IL-1 enhances the efficacy of MSC transplantation in DSS-induced colitis," Cellular&Molecular Immunology, vol. 9, no. 6, pp. 473-481, 2012.
29. R. Carrero, I. Cerrada, E. Lledo et al., "IL1 induces mesenchymal stem cells migration and leucocyte chemotaxis throughNF-B," Stem Cell Reviews and Reports, vol. 8, no. 3, pp. 905-916, 2012.
30. Z. Tu, Q. Li,H. Bu, and F. Lin, "Mesenchymal stemcells inhibit complement activation by secreting factor H," Stem Cells and Development, vol. 19, no. 11, pp. 1803-1809, 2010.
31. D.Ti,H.Hao,C. Tonget et al., "LPS-preconditionedmesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b," Journal of Translational Medicine, vol. 13, no. 1, article 308, 2015.
32. L. A. Pobezinsky, R. Etzensperger, S. Jeurling et al., "Let-7 microRNAs target the lineage-specific transcription factor PLZF to regulate terminal NKT cell differentiation and effector function," Nature Immunology, vol. 16, no. 5, pp. 517-524, 2015.
33. P. Fuenzalida, M. Kurte, C. Fernandez-ORyan et al., "Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal stromal cells in a dextran sulfate sodium-induced colitis model," Cytotherapy, vol. 18, no. 5, pp. 630-641, 2016.
34. A. Gray, T. Maguire, R. Schloss, and M. L. Yarmush, "Identification of IL-1 and LPS as optimal activators of monolayer and alginate-encapsulatedmesenchymal stromal cell immunomodulation using design of experiments and statistical methods," Biotechnology Progress, vol. 31, no. 4, pp. 1058-1070, 2015.
35. W. Gu, L. Song, X.-M. Li, D. Wang, X.-J. Guo, and W.-G. Xu, "Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways," Scientific Reports, vol. 5, article 8733, 2015.
36. G. Zhao, H. Miao, X. Li et al., "TGF-3-induced miR-494 inhibits macrophage polarization via suppressing PGE2 secretion in mesenchymal stem cells," FEBS Letters, vol. 590, no. 11, pp. 1602-1613, 2016.
37. J.H. Ylostalo,T. J. Bartosh,K.Coble, andD. J.Prockop, "Human mesenchymal stem/stromal cells cultured as spheroids are selfactivated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype," Stem Cells, vol. 30, no. 10, pp. 2283-2296, 2012.
38. T. J. Bartosh, J. H. Ylostalo, N. Bazhanov, J. Kuhlman, and D. J. Prockop, "Dynamic compaction of human mesenchymal stem/precursor cells into spheres self-activates caspasedependent il1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1)," Stem Cells, vol. 31, no. 11, pp. 2443-2456, 2013.
39. T. J. Bartosh, J. H. Ylostalo, A. Mohammadipoor et al., "Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 31, pp. 13724-13729, 2010.
40. J. A. Zimmermann and T. C. Mcdevitt, "Pre-conditioning mesenchymal stromal cell spheroids for immunomodulatory paracrine factor secretion," Cytotherapy, vol. 16, no. 3, pp. 331-345, 2014.
41. J. H. Ylostalo, T. J. Bartosh, A. Tiblow, and D. J. Prockop, "Unique characteristics of human mesenchymal stromal/ progenitor cells pre-activated in 3-dimensional cultures under different conditions," Cytotherapy, vol. 16, no. 11, pp. 1486-1500, 2014.
42. W. Cao, K. Cao, J. Cao,Y.Wang, and Y. Shi, "Mesenchymal stem cells and adaptive immune responses," Immunology Letters, vol. 168, no. 2, pp. 147-153, 2015.
43. E. Ben-Ami, S. Berrih-Aknin, and A. Miller, "Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases," Autoimmunity Reviews, vol. 10, no. 7, pp. 410-415, 2011.
44. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses," Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
45. L. M. Ball and R. M. Egeler, "Acute GvHD: pathogenesis and classification," Bone Marrow Transplantation, vol. 41, no. 2, pp. S58-S64, 2008.
46. L. Sun, K. Akiyama, H. Zhang et al., "Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans," STEM CELLS, vol. 27, no. 6, pp. 1421-1432, 2009.
47. A. Papadopoulou, M. Yiangou, E. Athanasiou et al., "Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis," Annals of the Rheumatic Diseases, vol. 71, no. 10, pp. 1733-1740, 2012.
48. W. Ge, J. Jiang, M. L. Baroja et al., "Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance," American Journal of Transplantation, vol. 9, no. 8, pp. 1760-1772, 2009.
49. M.W. Lee, S. Ryu,D. S. Kim, K.W. Sung,H. H. Koo, andK.H. Yoo, "Strategies to improve the immunosuppressive properties of human mesenchymal stem cells," Stem Cell Research and Therapy, vol. 6, no. 1, p. 1, 2015.
50. T. P. Frazier, J. M. Gimble, I. Kheterpal, and B. G. Rowan, "Impact of low oxygen on the secretome of human adiposederived stromal/stem cell primary cultures," Biochimie, vol. 95, no. 12, pp. 2286-2296, 2013.
51. E. Andreeva, I. Andrianova, J. Rylova, A. Gornostaeva, P. Bobyleva, and L. Buravkova, "Proinflammatory interleukins production by adipose tissue-derived mesenchymal stromal cells: the impact of cell culture conditions and cell-to-cell interaction," Cell Biochemistry and Function, vol. 33,no. 6, pp. 385-392, 2015.
52. L. Xu, X. Wang, J. Wang et al., "Hypoxia-induced secretion of IL-10 from adipose-derived mesenchymal stem cell promotes growth and cancer stem cell properties of Burkitt lymphoma," Tumor Biology, vol. 37, no. 6, pp. 7835-7842, 2016.
53. C. M. Jiang, J. Liu, J. Y. Zhao et al., "Effects of hypoxia on the immunomodulatory properties of human gingiva-derived mesenchymal stemcells," Journal of Dental Research, vol. 94,no. 1, pp. 69-77, 2015.
54. M. Roemeling-Van Rhijn, F. K. F. Mensah, S. S. Korevaar et al., "Effects of hypoxia on the immunomodulatory properties of adipose tissue-derived mesenchymal stem cells," Frontiers in Immunology, vol. 4, article 203, 2013.
55. A. U. Engela, C. C. Baan, A. M. A. Peeters, W. Weimar, and M. J. Hoogduijn, "Interaction between adipose tissuederived mesenchymal stem cells and regulatory T-cells," Cell Transplantation, vol. 22, no. 1, pp. 41-54, 2013.
56. K. English, R. Tonlorenzi, G. Cossu, and K. J.Wood, "Mesoangioblasts suppress T cell proliferation through IDO and PGE-2-dependent pathways," Stem Cells and Development, vol. 22, no. 3, pp. 512-523, 2013.
57. P. I. Bobyleva, E. R. Andreeva, A. N. Gornostaeva, and L. B. Buravkova, "Tissue-related hypoxia attenuates proinflammatory effects of allogeneic pbmcs on adipose-derived stromal cells in vitro," Stem Cells International, vol. 2016, Article ID 4726267, 13 pages, 2016.
58. M. Krampera, L. Cosmi, R. Angeli et al., "Role for interferon-in the immunomodulatory activity of human bone marrow mesenchymal stem cells," STEM CELLS, vol. 24, no. 2, pp. 386-398, 2006.
59. S. Tipnis, C. Viswanathan, and A. S. Majumdar, "Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO," Immunology and Cell Biology, vol. 88, no. 8, pp. 795-806, 2010.
60. R. Chinnadurai, I. B. Copland, S. R. Patel, and J. Galipeau, "IDO-independent suppression of T cell effector function by IFN-licensed humanmesenchymal stromal cells,"The Journal of Immunology, vol. 192, no. 4, pp. 1491-1501, 2014.
61. P. Jin, Y. Zhao, H. Liu et al., "Interferon-and tumor necrosis factor-polarize bone marrow stromal cells uniformly to a Th1 phenotype," Scientific Reports, vol. 6, Article ID26345, 2016.
62. S.Ma,N. Xie,W. Li, B.Yuan, Y. Shi, and Y.Wang, "Immunobiology of mesenchymal stem cells," Cell Death & Differentiation, vol. 21, no. 2, pp. 216-225, 2014.
63. J. Cuerquis, R. Romieu-Mourez, M. Francois et al., "Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon-and tumor necrosis factor-stimulation," Cytotherapy, vol. 16, no. 2, pp. 191-202, 2014.
64. H. Li,W.Wang, G.Wang et al., "Interferon-and tumor necrosis factor-promote the ability of human placenta-derived mesenchymal stromal cells to express programmed death ligand-2 and induce the differentiation of CD4+ interleukin-10+ and CD8+ interleukin-10+ Treg subsets," Cytotherapy, vol. 17, no. 11, pp. 1560-1571, 2015.
65. S. J. Prasanna, D. Gopalakrishnan, S. R. Shankar, and A. B. Vasandan, "Pro-inflammatory cytokines, IFN and TNF, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially," PLoS ONE, vol. 5, no. 2, article e9016, 2010.
66. K. N. Sivanathan, D. M. Rojas-Canales, C. M. Hope et al., "Interleukin-17A-induced human mesenchymal stem cells are superior modulators of immunological function," Stem Cells, vol. 33, no. 9, pp. 2850-2863, 2015.
67. F. Gieseke, A. Kruchen, N. Tzaribachev, F. Bentzien, M. Dominici, and I. Muller, "Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress Tcell proliferation," European Journal of Immunology, vol. 43, no. 10, pp. 2741-2749, 2013.
68. C.Wu,T.Thalhamer,R. F. Franca et al., "Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells," Immunity, vol. 41, no. 2, pp. 270-282, 2014.
69. J. A. Ankrum, R. G. Dastidar, J. F. Ong, O. Levy, and J. M. Karp, "Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids," Scientific Reports, vol. 4, Article ID 04645, 2014.
70. C.-W. Chen, M. Okada, J. D. Proto et al., "Human pericytes for ischemic heart repair," Stem Cells, vol. 31, no. 2, pp. 305-316, 2013.
71. C. Toma, W. R. Wagner, S. Bowry, A. Schwartz, and F. Villanueva, "Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics," Circulation Research, vol. 104, no. 3, pp. 398-402, 2009.